• CloudMD has nominated Duncan Hannay and Karen Adams to the company’s board of directors
  • Duncan is the current CEO of OLG Corporation
  • Karen is the current president of CloudMD as well as its Global Head, Enterprise Health Solutions
  • Both candidates offer more than 20 years of experience creating growth in business
  • Mark Kohler (Chairman), Christopher Cherry (Independent) and Essam Hazma (CEO) are up for re-election to the board
  • CloudMD has appointed KPMG LLP, Chartered Professional Accountants as the company’s independent auditors
  • CloudMD is digitizing the delivery of healthcare by providing a patient-centric approach, with an emphasis on continuity of care.
  • CloudMD Software & Services Inc. (DOC) is down 3.11 per cent, trading at C$1.56 per share at 1:15 pm ET

CloudMD has nominated Duncan Hannay and Karen Adams to the company’s board of directors.

Duncan is the current CEO of OLG Corporation. Karen is the current president of CloudMD as well as its Global Head, Enterprise Health Solutions.

Both candidates offer more than 20 years of experience creating growth in business.

Dr. Essam Hazma, CEO of CloudMD said he is excited to have Hannay and Adams up for nomination.

“We are thrilled to welcome Duncan and Karen to our Board of Directors as their collective experience and leadership will be extremely valuable to the continued growth of our company… Each of these outstanding individuals brings valuable expertise and insight that will help position CloudMD for long-term success as an innovative healthcare company.”

Up for re-election for the board of directors are Mark Kohler (Chairman), Christopher Cherry (Independent) and Essam Hazma (CEO).

CloudMD also announces that it has appointed KPMG LLP, Chartered Professional Accountants as the company’s independent auditors to hold office until the end of the next annual general meeting of shareholders.

As of Sept. 9th, 2021, CloudMD’s predecessor auditors resigned, and KPMG has been appointed to fill their vacancy for the fiscal year ended on Dec. 31st, 2021.

CloudMD has granted stock options and RSU’s in course to certain directors and officers under its Stock Option Plan and RSU Plan to purchase 1,250,000 shares of the company. The price of the stock options granted was set at $1.75 per share.

CloudMD is transforming healthcare by using technology and works with hybrid primary care clinics, specialist care, telemedicine, mental health support, healthcare navigation, educational resources, and AI’s.

CloudMD Software & Services Inc. (DOC) is down 3.11 per cent, trading at C$1.56 per share at 1:15 pm ET.

More From The Market Online

PharmAla Biotech launches educational portal for MDMA

PharmAla Biotech (CSE:MDMA) launches its Prescribers Portal for medical practitioners to learn more about MDMA.

Cancer-fighting pharma stock eyes 2027 regulatory approval

Theralase Technologies (TSXV:TLT), a cancer-fighting pharma stock, expands its team with two clinical research associates.

PharmaDrug-PharmaTher Holdings JV submits clinical, regulatory package

Sairiyo Therapeutics, a PharmaDrug (CSE:PHRX) and PharmaTher Holdings (CSE:PHRM) joint venture, pursues a human clinical study in Australia.